AD109 met the primary endpoint, mean change in apnea-hypopnea index (AHI, p=0.001) at 26 weeks, across a broad range of people with mild, moderate and severe obstructive sleep apnea Study ...

You may have heard of sleep apnea. It’s a common disorder that affects about 39 million American adults. But you may not be familiar with its cousin, hypopnea. Apnea and hypopnea are different ...

AD109 is a once daily pill that consists of aroxybutynin, an antimuscarinic, and atomoxetine, a selective norepinephrine reuptake inhibitor.

Sleep apnea’s severity is determined by something called your apnea-hypopnea index (AHI): the number of ... can sometimes get ...

Frontoparietal cerebrovascular pathology is linked to oxygenation during REM sleep, indicating possible connection to Alzheimer Disease.

The main goal was to measure at six months the change in the apnea-hypopnea index, a scale used to measure the breathing reductions or interruptions during sleep (the higher the score, the more ...

Researchers used this home sleep study data to determine each person’s apnea-hypopnea index, the number of times per hour that breathing stops or is reduced. Researchers then compared how well ...

Two randomized controlled trials show reduction in AHI; significant improvements seen in all secondary end points. (HealthDay News) — Tirzepatide reduces the apnea-hypopnea index (AHI) among ...

The trials’ main goal was improvement on a metric known as the apnea-hypopnea index, or AHI, the number of breathing disruptions during an hour of sleep. In both studies, the mean AHI to start ...

Using the apnea-hypopnea index of AHI3a, which assesses breathing interruptions during sleep, the researchers found that patients on the highest dose of sulthiame had 39.9% lower frequency of ...